The agency is charged with positioning the Swedish firm as a leader in the drug development and manufacturing services sector
Recipharm is looking to grow by 20 per cent per year and aims to challenge the dominance of the world's top three contract manufacturing organisations.
De Facto will handle an extensive international media outreach programme and secure pieces in influential sector publications.
It will also highlight Recipharm's in-house development and formulation expertise through a series of articles and case studies in the technical press.
De Facto co-founder and director Kevin Payne will lead the account.